ETNB
Price:
$8.47
Market Cap:
$897.06M
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.[Read more]
Industry
Biotechnology
IPO Date
2019-11-11
Stock Exchange
NASDAQ
Ticker
ETNB
According to 89bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.32. This represents a change of -25.19% compared to the average of -5.77 of the last 4 quarters.
The mean historical PE Ratio of 89bio, Inc. over the last ten years is -4.62. The current -4.32 PE Ratio has changed 9.25% with respect to the historical average. Over the past ten years (40 quarters), ETNB's PE Ratio was at its highest in in the June 2022 quarter at -0.65. The PE Ratio was at its lowest in in the December 2020 quarter at -9.63.
Average
-4.62
Median
-4.97
Minimum
-7.92
Maximum
-1.07
Discovering the peaks and valleys of 89bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 637.96%
Maximum Annual PE Ratio = -1.07
Minimum Annual Increase = -81.79%
Minimum Annual PE Ratio = -7.92
Year | PE Ratio | Change |
---|---|---|
2023 | -5.59 | 28.74% |
2022 | -4.34 | 48.99% |
2021 | -2.91 | -63.20% |
2020 | -7.92 | 637.96% |
2019 | -1.07 | -81.79% |
The current PE Ratio of 89bio, Inc. (ETNB) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.28
5-year avg
-4.37
10-year avg
-4.62
89bio, Inc.’s PE Ratio is greater than Madrigal Pharmaceuticals, Inc. (-10.23), less than Pliant Therapeutics, Inc. (-4.19), greater than Arcellx, Inc. (-70.75), greater than Stoke Therapeutics, Inc. (-7.92), greater than Day One Biopharmaceuticals, Inc. (-7.39), less than X4 Pharmaceuticals, Inc. (7.41), less than Inozyme Pharma, Inc. (-3.48), less than Acumen Pharmaceuticals, Inc. (-2.06), greater than Mereo BioPharma Group plc (-18.18), greater than Viking Therapeutics, Inc. (-61.76), greater than Intercept Pharmaceuticals, Inc. (-13.55), greater than Terns Pharmaceuticals, Inc. (-6.06), greater than Akero Therapeutics, Inc. (-8.95), greater than Reata Pharmaceuticals, Inc. (-89.36), less than HOOKIPA Pharma Inc. (-1.22), less than TG Therapeutics, Inc. (33.32), less than Hepion Pharmaceuticals, Inc. (-0.15),
Company | PE Ratio | Market cap |
---|---|---|
-10.23 | $5.30B | |
-4.19 | $782.51M | |
-70.75 | $3.83B | |
-7.92 | $773.92M | |
-7.39 | $1.25B | |
7.41 | $109.78M | |
-3.48 | $312.42M | |
-2.06 | $133.38M | |
-18.18 | $664.26M | |
-61.76 | $6.00B | |
-13.55 | $794.69M | |
-6.06 | $549.60M | |
-8.95 | $1.83B | |
-89.36 | $6.57B | |
-1.22 | $159.50M | |
33.32 | $3.41B | |
-0.15 | $4.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 89bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like 89bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is 89bio, Inc.'s PE Ratio?
How is the PE Ratio calculated for 89bio, Inc. (ETNB)?
What is the highest PE Ratio for 89bio, Inc. (ETNB)?
What is the 3-year average PE Ratio for 89bio, Inc. (ETNB)?
What is the 5-year average PE Ratio for 89bio, Inc. (ETNB)?
How does the current PE Ratio for 89bio, Inc. (ETNB) compare to its historical average?